Gemphire Therapeutics Inc. (NASDAQ:GEMP) had its price target increased by Jefferies Group LLC to $32.00 in a report released on Tuesday, August 1st, MarketBeat Ratings reports. The firm currently has a “buy” rating on the stock. Jefferies Group LLC’s target price points to a potential upside of 222.26% from the company’s previous close. Jefferies Group also issued estimates for Gemphire Therapeutics’ FY2018 earnings at ($1.87) EPS, FY2019 earnings at ($1.90) EPS, FY2020 earnings at ($1.38) EPS and FY2021 earnings at ($1.07) EPS.

Several other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Gemphire Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. Canaccord Genuity reissued a “buy” rating and issued a $17.00 price target on shares of Gemphire Therapeutics in a research note on Wednesday, May 31st. Finally, Piper Jaffray Companies initiated coverage on shares of Gemphire Therapeutics in a research note on Monday, April 10th. They issued an “overweight” rating and a $30.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $24.33.

Shares of Gemphire Therapeutics (GEMP) traded down 8.2588% during mid-day trading on Tuesday, reaching $9.1099. 230,322 shares of the company’s stock traded hands. The stock’s market capitalization is $96.56 million. Gemphire Therapeutics has a 12-month low of $7.25 and a 12-month high of $21.59. The company’s 50-day moving average price is $14.60 and its 200-day moving average price is $11.52.

Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.18. Analysts anticipate that Gemphire Therapeutics will post ($2.78) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Gemphire Therapeutics Inc. (GEMP) Given New $32.00 Price Target at Jefferies Group LLC” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/04/jefferies-group-llc-boosts-gemphire-therapeutics-inc-gemp-price-target-to-32-00.html.

Several institutional investors have recently bought and sold shares of GEMP. Northpointe Capital LLC bought a new position in Gemphire Therapeutics during the second quarter worth $3,472,000. Cambridge Investment Research Advisors Inc. bought a new position in Gemphire Therapeutics during the first quarter worth $1,581,000. Exchange Capital Management Inc. bought a new position in Gemphire Therapeutics during the first quarter worth $444,000. Renaissance Technologies LLC bought a new position in Gemphire Therapeutics during the first quarter worth $184,000. Finally, Norris Perne & French LLP MI bought a new position in Gemphire Therapeutics during the first quarter worth $110,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.